Tempest Therapeutics, Inc. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6f74df77-6afe-4f5b-b7af-bd8060e9c642/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-26.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-130490 |
| FY 2024 | $-42.0M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-046144 |
| FY 2023 | $-29.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-033555 |
| FY 2022 | $-34.6M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-009237 |
| FY 2021 | $-27.0M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-007717 |
| FY 2020 | $-19.3M | 2020-01-01 – 2020-12-31 | evidence 0001628280-22-007717 |
| FY 2019 | $-45.4M | 2019-01-01 – 2019-12-31 | evidence 0001544227-20-000004 |
| FY 2018 | $-26.9M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-002660 |
| FY 2017 | $-84.3M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-002660 |
| FY 2016 | $-81.0M | 2016-01-01 – 2016-12-31 | evidence 0001544227-17-000002 |
| FY 2015 | $-72.0M | 2015-01-01 – 2015-12-31 | evidence 0001544227-16-000008 |
| FY 2014 | $-47.9M | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-002286 |
| FY 2013 | $-52.9M | 2011-04-05 – 2014-03-31 | evidence 0001104659-14-036131 |
| FY 2012 | $-21.3M | 2011-04-05 – 2013-03-31 | evidence 0001104659-13-041862 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Tempest Therapeutics, Inc. — all facts · Revenue · Net Income